Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13943897 | 1.00 | GHSR (0.39) | GHSRCHRM1HTR2AMCHR1CHKA | |
| SCHEMBL3652735 | 0.89 | GHSR (0.50) | GHSRLTA4H | |
| SCHEMBL13943577 | 0.89 | GHSR (0.50) | GHSRLTA4H | |
| SCHEMBL31142652 | 0.83 | CHRNB4 (0.36) | — | |
| SCHEMBL3648982 | 0.80 | CNR2 (0.42) | GHSRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13943896 | 0.80 | CNR2 (0.42) | GHSRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3651613 | 0.79 | TAAR1 (0.43) | GHSRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13942547 | 0.79 | TAAR1 (0.43) | GHSRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11192062 | 0.75 | LTA4H (0.47) | GHSRCHRM1HTR2AMCHR1SLC6A2 | |
| SCHEMBL3644249 | 0.72 | REN (0.59) | GHSRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| CN-101765587-A | 2-azetidinemethanamines and 2-pyrrolidinemethanamines as TAAR ligands | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | claimed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | claimed |
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389507-B2 | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | GALLEY GUIDO (DE) | 2013-01-03 | — | — | US | disclosed |
| CN-101765587-A | 2-azetidinemethanamines and 2-pyrrolidinemethanamines as TAAR ligands | HOFFMANN LA ROCHE | 2010-06-30 | — | — | CN | disclosed |
| EP-2183216-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009016048-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029962-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | GHSR 72/4885CHRM1 136/4885HTR2A 13/4885 |
| US-20130005988-A1 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS | TAAR1, TAAR5, NPY2R | GHSR 72/4885CHRM1 136/4885HTR2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.